The stock plunged almost 40% today after the final nail in the coffin for senicapoc. I don't think it was much of a surprise at all that this compound failed this latest trial given the prior failure in another indication and the prior Phase 2a study in asthma that didn't reach statistical significance on any endpoints.
Now the market cap is down to about $20 million. They do still have their lead drug targeting potassium channels for pain and epilepsy that just entered PoC trials. There's also the large partnership that PFE entered into with them a few years ago targeting sodium channel blockers for pain and related conditions. PFE recently renewed this research agreement for another year.
News 
Market Data 
Discover 
AI
